Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 3/2011

01.03.2011 | Article

Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury

verfasst von: T. K. Ali, M. M. H. Al-Gayyar, S. Matragoon, B. A. Pillai, M. A. Abdelsaid, J. J. Nussbaum, A. B. El-Remessy

Erschienen in: Diabetologia | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Diabetic retinopathy, the leading cause of blindness in working-age Americans, is characterised by reduced neurotrophic support and increased proinflammatory cytokines, resulting in neurotoxicity and vascular permeability. We sought to elucidate how oxidative stress impairs homeostasis of nerve growth factor (NGF) and its precursor, proform of NGF (proNGF), to cause neurovascular dysfunction in the eye of diabetic patients.

Methods

Levels of NGF and proNGF were examined in samples from human patients, from retinal Müller glial cell line culture cells and from streptozotocin-induced diabetic animals treated with and without atorvastatin (10 mg/kg daily, per os) or 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinato iron (III) chloride (FeTPPs) (15 mg/kg daily, i.p.) for 4 weeks. Neuronal death and vascular permeability were assessed by TUNEL and extravasation of BSA-fluorescein.

Results

Diabetes-induced peroxynitrite formation impaired production and activity of matrix metalloproteinase-7 (MMP-7), which cleaves proNGF extracellularly, leading to accumulation of proNGF and reducing NGF in samples from diabetic retinopathy patients and experimental models. Treatment of diabetic animals with atorvastatin exerted similar protective effects that blocked peroxynitrite using FeTPPs, restoring activity of MMP-7 and hence the balance between proNGF and NGF. These effects were associated with preservation of blood–retinal barrier integrity, preventing neuronal cell death and blocking activation of RhoA and p38 mitogen-activated protein kinase (p38MAPK) in experimental and human samples.

Conclusions/interpretation

Oxidative stress plays an unrecognised role in causing accumulation of proNGF, which can activate a common pathway, RhoA/p38MAPK, to mediate neurovascular injury. Oral statin therapy shows promise for treatment of diabetic retinopathy.
Literatur
1.
Ali TK, Matragoon S, Pillai BA, Liou GI, El-Remessy AB (2008) Peroxynitrite mediates retinal neurodegeneration by inhibiting NGF survival signal in experimental and human diabetes. J Diabetes 57:889–898CrossRef
2.
Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783–791CrossRefPubMed
3.
El-Remessy AB, Al-Shabrawey M, Khalifa Y, N-t T, Caldwell RB, Liou GI (2006) Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168:235–244CrossRefPubMed
4.
Adamis AP, Miller JW, Bernal MT et al (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed
5.
Ali TK, El-Remessy AB (2009) Diabetic retinopathy: current management and experimental therapeutic targets. Pharmacotherapy 29:182–192CrossRefPubMed
6.
Azar ST, Major SC, Safieh-Garabedian B (1999) Altered plasma levels of nerve growth factor and transforming growth factor-beta2 in type-1 diabetes mellitus. Brain Behav Immun 13:361–366CrossRefPubMed
7.
Park KS, Kim SS, Kim JC et al (2008) Serum and tear levels of nerve growth factor in diabetic retinopathy patients. Am J Ophthalmol 145:432–437CrossRefPubMed
8.
Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science (New York, NY) 294:1945–1948CrossRef
9.
Hempstead BL (2009) Commentary: regulating proNGF action: multiple targets for therapeutic intervention. Neurotox Res 16:255–260CrossRefPubMed
10.
Yoshida Y, Yamagishi SI, Matsui T et al (2009) Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes/Metab Res Rev 25:678–686CrossRef
11.
Abdelsaid MA, Pillai BA, Matragoon S, Prakash R, Al-Shabrawey M, El-Remessy AB (2010) Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. J Pharmacol Exp Ther 332:125–134CrossRefPubMed
12.
El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB (2003) Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162:1995–2004CrossRefPubMed
13.
Al-Shabrawey M, El-Remessy AB, Ma G et al (2008) Mechanisms of statin’s protective actions in diabetic retinopathy: role of NAD(P)H oxidase and STAT3. IOVS 49:3231–3238
14.
Linseman DA, Loucks FA (2008) Diverse roles of Rho family GTPases in neuronal development, survival, and death. Front Biosci 13:657–676CrossRefPubMed
15.
Sarthy VP, Brodjian SJ, Dutt K, Kennedy BN, French RP, Crabb JW (1998) Establishment and characterization of a retinal Muller cell line. Investig Ophthalmol Vis Sci 39:212–216
16.
El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB (2003) High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Investig Ophthalmol Vis Sci 44:3135–3143CrossRef
17.
Romero MJ, Platt DH, Tawfik HE et al (2008) Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102:95–102CrossRefPubMed
18.
Antonetti DA, Barber AJ, Bronson SK et al (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55:2401–2411CrossRefPubMed
19.
Fletcher EL, Phipps JA, Wilkinson-Berka JL (2005) Dysfunction of retinal neurons and glia during diabetes. Clin Exp Optom 88:132–145CrossRefPubMed
20.
Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW (2002) Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 47(Suppl 2):S253–S262CrossRefPubMed
21.
Drel VR, Pacher P, Ali TK et al (2008) Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med 21:667–676PubMed
22.
Du Y, Smith MA, Miller CM, Kern TS (2002) Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 80:771–779CrossRefPubMed
23.
Joussen AM, Poulaki V, Le ML et al (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452PubMed
24.
Shimura M, Yasuda K, Nakazawa T et al (2009) Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 247:1617–1624CrossRefPubMed
25.
El-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB (2005) Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 118:243–252CrossRefPubMed
26.
Vargas MR, Pehar M, Cassina P, Estevez AG, Beckman JS, Barbeito L (2004) Stimulation of nerve growth factor expression in astrocytes by peroxynitrite. In Vivo 18:269–274PubMed
27.
Domeniconi M, Hempstead BL, Chao MV (2007) Pro-NGF secreted by astrocytes promotes motor neuron cell death. Mol Cell Neurosci 34:271–279CrossRefPubMed
28.
Yune TY, Lee JY, Jung GY et al (2007) Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 27:7751–7761CrossRefPubMed
29.
Srinivasan B, Roque CH, Hempstead BL, Al-Ubaidi MR, Roque RS (2004) Microglia-derived pronerve growth factor promotes photoreceptor cell death via p75 neurotrophin receptor. J Biol Chem 279:41839–41845CrossRefPubMed
30.
Wielockx B, Libert C, Wilson C (2004) Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation? Cytokine Growth Factor Rev 15:111–115CrossRefPubMed
31.
McLennan SV, Kelly DJ, Schache M et al (2007) Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy? Kidney Int 72:481–488CrossRefPubMed
32.
Abdel Wahab N, Mason RM (1996) Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Biochem J 320:777–783PubMed
33.
Fu X, Kassim SY, Parks WC, Heinecke JW (2003) Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem 278:28403–28409CrossRefPubMed
34.
Casaccia-Bonnefil P, Carter BD, Dobrowsky RT, Chao MV (1996) Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 383:716–719CrossRefPubMed
35.
von Bartheld CS (1998) Neurotrophins in the developing and regenerating visual system. Histol Histopathol 13:437–459
36.
Semenova MM, Maki-Hokkonen AM, Cao J et al (2007) Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat Neurosci 10:436–443PubMed
37.
Dubreuil CI, Winton MJ, McKerracher L (2003) Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 162:233–243CrossRefPubMed
38.
Nwariaku FE, Chang J, Zhu X et al (2002) The role of p38 map kinase in tumor necrosis factor-induced redistribution of vascular endothelial cadherin and increased endothelial permeability. Shock 18:82–85CrossRefPubMed
39.
Nwariaku FE, Rothenbach P, Liu Z, Zhu X, Turnage RH, Terada LS (2003) Rho inhibition decreases TNF-induced endothelial MAPK activation and monolayer permeability. J Appl Physiol 95:1889–1895PubMed
40.
Bogatcheva NV, Adyshev D, Mambetsariev B, Moldobaeva N, Verin AD (2007) Involvement of microtubules, p38, and Rho kinases pathway in 2-methoxyestradiol-induced lung vascular barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 292:L487–L499CrossRefPubMed
41.
Kahles T, Luedike P, Endres M et al (2007) NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38:3000–3006CrossRefPubMed
42.
Guo X, Wang L, Chen B et al (2009) ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol 297:H238–H246CrossRefPubMed
43.
Poulaki V, Qin W, Joussen AM et al (2002) Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Investig 109:805–815PubMed
44.
Issbrucker K, Marti HH, Hippenstiel S et al (2003) p38 MAP kinase—a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J 17:262–264PubMed
45.
Elewa HF, Kozak A, El-Remessy AB et al (2009) Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. J Pharmacol Exp Ther 330:532–540CrossRefPubMed
46.
Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, Caldwell RW (2006) Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 319:386–395CrossRefPubMed
47.
Miyahara S, Kiryu J, Yamashiro K et al (2004) Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol 164:1697–1706CrossRefPubMed
48.
Tsubouchi H, Inoguchi T, Sonta T et al (2005) Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 39:444–452CrossRefPubMed
Metadaten
Titel
Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury
verfasst von
T. K. Ali
M. M. H. Al-Gayyar
S. Matragoon
B. A. Pillai
M. A. Abdelsaid
J. J. Nussbaum
A. B. El-Remessy
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 3/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1935-1

Weitere Artikel der Ausgabe 3/2011

Diabetologia 3/2011 Zur Ausgabe

Article

Postprandial hyperaminoacidaemia overcomes insulin resistance of protein anabolism in men with type 2 diabetes

Article

Cumulative cost of prescription medication in outpatients with type 1 diabetes in Finland

Letter

Intensified glucose lowering in type 2 diabetes: don’t throw the baby out with the bathwater

Article

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

Letter

Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer. Reply to Yang XL, Ma RCW, Chan JCN [letter]

Erratum

Erratum: Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise